November 6, 2016. Since sugammadex has the ability to quickly reverse the paralysis induced by neuromuscular blockers like rocuronium, it represents an innovative new option to improve surgical recovery. However, as with every new drug, we need to be certain the benefits outweigh the harms.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Comments on Nondiscrimination in Health Programs and Activities
November 9, 2015. We fully support the Administration’s efforts to “prohibit discrimination on the basis of race, color, national origin, sex, age, or disability in certain health programs and activities.”
Read More »NCHR Testimony at FDA Meeting on Risk Evaluation and Mitigation Strategies (REMS)
October 5, 2015. Our Center strongly supports research and programs to improve drug safety. We remember when REMS were first proposed in legislation, the reason was to enable FDA to approve drugs with serious risks by providing a mechanism to mitigate those risks.
Read More »NCHR at FDA Meeting on Essure Contraceptive
September 24, 2015. If the product is to be on the market, who should do the studies to accurately determine the short-term and long-term effectiveness and side effects? The company’s track record and response to the women’s reported complications is not acceptable. Any additional research should be conducted independently of the company so that patients can have confidence in its accuracy.
Read More »Comments to the U.S. Consumer Product Safety Commission Regarding Supplemental Mattresses
October 13, 2015. The National Center for Health Research supports Keeping Babies Safe’s (KBS) petition that requests a ban on supplemental mattresses for play yards with non-rigid sides. These mattresses present an unreasonable risk of injury or death (suffocation) to infants and toddlers.
Read More »